“I have no doubt PRP represents a new therapeutic drug class with significant potential [because] when confirming PRP’s effectiveness across a broad range of cancers, we also confirmed a synergistic response between the two proenzymes to the majority of cancer cell lines tested,” says Dr. Julian Kenyon, Propane’s Chief Scientific Officer. “We also noticed that for some cancer types, multiple combinations of the two proenzymes proved to be effective.”
Propanc recently met with the Medicines and Healthcare Products Regulatory Agency (MHRA) to discuss formal pre-clinical and clinical development of PRP. In addition, the company said it intends to apply for orphan drug designation for pancreatic and ovarian cancers in the US and Europe in the near future.
Propanc recently met with the Medicines and Healthcare Products Regulatory Agency (MHRA) to discuss formal pre-clinical and clinical development of PRP. In addition, the company said it intends to apply for orphan drug designation for pancreatic and ovarian cancers in the US and Europe in the near future.
